Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study

Abstract

Background:Clinical observations indicated an increased risk of developing prostate cancer in gout patients. Chronic inflammation is postulated to be one crucial mechanism for prostate carcinogenesis. Allopurinol, a widely used antigout agent, possesses potent anti-inflammation capacity. We elucidated whether allopurinol decreases the risk of prostate… (More)
DOI: 10.1038/pcan.2017.14

Topics

6 Figures and Tables

Cite this paper

@article{Shih2017LongtermAU, title={Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study}, author={H-J Shih and M-C Kao and P. J. Tsai and Y N Fan and C-J. Huang}, journal={Prostate Cancer and Prostatic Diseases}, year={2017}, volume={20}, pages={328-333} }